-
Mar 20, 2024 | 
nejm.org | Elizabeth G. Phimister
March 21, 2024N Engl J Med 2024; 390:1143-1146 DOI: 10.1056/NEJMe2400475Elizabeth G. Phimister, Ph.D., Editor This editorial describes the science behind a study of an autoimmune response against cytokines in persons with thymoma and severe infections. Funding and Disclosures Disclosure forms provided by the authors are available with the full text of this editorial at NEJM.org.
-
Feb 21, 2024 | 
nejm.org | Elizabeth G. Phimister
February 21, 2024 DOI: 10.1056/NEJMe2313802Elizabeth G. Phimister, Ph.D., Editor This editorial describes the science behind clinical trials testing elafibranor and seladelpar in the treatment of primary biliary cholangitis. Funding and Disclosures Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org. This editorial was published on February 21, 2024, at NEJM.org.
-
Jan 3, 2024 | 
nejm.org | Elizabeth G. Phimister
This article is available to subscribers. Subscribe now. Already have an account? Sign in EditorialScience Behind the StudyFree PreviewList of authors. January 4, 2024N Engl J Med 2024; 390:82-85 DOI: 10.1056/NEJMe2311358Elizabeth G. Phimister, Ph.D., Editor This editorial describes the science behind a trial involving a breach of the blood−brain barrier to deliver drugs to the brain.
-
Nov 22, 2023 | 
nejm.org | Elizabeth G. Phimister
November 23, 2023N Engl J Med 2023; 389:2010-2013 DOI: 10.1056/NEJMe2310332Elizabeth G. Phimister, Ph.D., Editor The treatment by liver transplantation of a patient with Mahvash disease, which is characterized by pancreatic neuroendocrine tumors, extends understanding of the biochemical processes undergirding its signs and symptoms.
-
Sep 6, 2023 | 
nejm.org | Dan L. Longo |Elizabeth G. Phimister
This article is available to subscribers. Subscribe now. Already have an account? Sign in EditorialScience behind the StudyFree PreviewList of authors. September 7, 2023N Engl J Med 2023; 389:953-957 DOI: 10.1056/NEJMe2304744Elizabeth G. Phimister, Ph.D., Editor This editorial describes the science behind a study that used base-edited CAR T cells to treat patients with T-cell lymphoblastic leukemia.
-
Aug 30, 2023 | 
nejm.org | Elizabeth G. Phimister
This article is available to subscribers. Subscribe now. Already have an account? Sign in EditorialScience behind the StudyFree PreviewList of authors. August 31, 2023N Engl J Med 2023; 389:853-856 DOI: 10.1056/NEJMe2304535Elizabeth G. Phimister, Ph.D., Editor This editorial describes the science behind a clinical trial of concizumab, an inhibitor of a naturally occurring anticoagulant, to treat hemophilia A and B.
-
Aug 30, 2023 | 
nejm.org | Jake shortt |Elizabeth G. Phimister
August 30, 2023 DOI: 10.1056/NEJMe2307370Elizabeth G. Phimister, Ph.D., Editor This editorial describes the science behind a study of mezigdomide, which augments the degradation of the proteins Ikaros and Aiolos, to treat multiple myeloma. Funding and Disclosures Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org. This editorial was published on August 30, 2023, at NEJM.org.
-
Aug 30, 2023 | 
nejm.org | Herbert Tilg |Elizabeth G. Phimister
This article is available to subscribers. Subscribe now. Already have an account? Sign in Clinical Implications of Basic ResearchFree PreviewList of authors. August 31, 2023N Engl J Med 2023; 389:859-861 DOI: 10.1056/NEJMcibr2303516Elizabeth G.
-
Aug 9, 2023 | 
nejm.org | Stuart G. Tangye |Isabelle Meyts |Elizabeth G. Phimister
From the Garvan Institute of Medical Research, Darlinghurst, NSW, and the School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales Sydney, Randwick, NSW — both in Australia (S.G.T.); and the Department of Immunology and Microbiology, Laboratory for Inborn Errors of Immunity, and the Department of Pediatrics, University Hospitals, Leuven, and Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Brussels — all in Belgium (I.M.).
-
Aug 2, 2023 | 
nejm.org | Stephen G. Waxman |Elizabeth G. Phimister
August 3, 2023N Engl J Med 2023; 389:466-469 DOI: 10.1056/NEJMe2305708Elizabeth G. Phimister, Ph.D., Editor This editorial describes the science behind clinical trials of an inhibitor of the sodium channel NaV1.8 to treat acute postoperative pain. Funding and Disclosures Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org.
